Nicotinic acetylcholine receptor antagonist effect of fluoxetine in rat hippocampal slices

Brain Research

Volumn 759, Issue 2, 1997, Pages 292-294

  Hennings, Esteban C P ^a   Kiss, Janos P ^a   Vizi, E Sylvester ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Fluoxetine; Hippocampus; Nicotine; Nicotinic acetylcholine receptor; Noradrenaline release

Indexed keywords

FLUOXETINE; MECAMYLAMINE; NICOTINIC RECEPTOR BLOCKING AGENT; SEROTONIN UPTAKE INHIBITOR;

ANIMAL TISSUE; ARTICLE; DOSE RESPONSE; DRUG EFFECT; HIPPOCAMPUS; MALE; NONHUMAN; NORADRENALIN BRAIN LEVEL; NORADRENALIN RELEASE; PRIORITY JOURNAL; RAT;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOXETINE; HIPPOCAMPUS; MALE; MECAMYLAMINE; NICOTINIC ANTAGONISTS; RATS; RATS, WISTAR;

EID: 0030749730     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)00343-0     Document Type: Article

References (17)

1. Arqueros L., Naquira D., Zunino E. Nicotine induced release of catecholamines from rat hippocampus and striatum. Biochem. Pharmacol. 27:1978;2667-2674.
2. Brazell M.P., Mitchell S.N., Gray J.A. Effect of acute administration of nicotine on in vivo release of noradrenaline in the hippocampus of freely moving rats: a dose-response and antagonist study. Neuropharmacology. 30:1991;823-833.
3. 3H]-dopamine release. Br. J. Pharmacol. 117:1996;595-606.
4. Dilsaver S.C., Davidson R.K. Fluoxetine subsensitizes a nicotinic mechanism involved in the regulation of core temperature. Life Sci. 41:1987;1165-1169.
5. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int. Clin. Psychopharmacol. 9(Suppl. 1):1994;19-26.
6. J.P. Kiss, K. Windisch, A. Balla, H. Sershen, A. Lajtha, Dual effect of DMPP on the resting release of noradrenaline from rat hippocampal slices, Brain Res. Bull., (1997) in press.
7. Lerner-Marmarosh N., Carrol F.I., Abood L.G. Antagonism of nicotine's action by cocaine analogs. Life Sci. 56:1995;67-70.
8. Martensson B., Nyberg S., Toresson G., Brodin E., Bertilsson L. Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid. Acta Psychiatr. Scand. 79:1989;586-596.
9. Mitchell S.N. Role of the locus coeruleus in the noradrenergic response to a systemic administration of nicotine. Neuropharmacology. 32:1993;937-949.
10. Pato M.T., Murphy D.L., DeVane C.L. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation [letter]. J. Clin. Psychopharmacol. 11:1991;224-225.
11. Rana B., McMorn S.O., Reeve H.L., Wyatt C.N., Vaughan P.F., Peers C. Inhibition of neuronal nicotinic acetylcholine receptors by imipramine and desipramine. Eur. J. Pharmacol. 250:1993;247-251.
12. Richardt G., Haass M., Neeb S., Hock M., Lang R.E., Schomig A. Nicotine-induced release of noradrenaline and neuropeptide Y in guinea pig heart. Klin. Wochenschr. 66(Suppl. 11):1988;21-27.
13. Sacaan A.I., Dunlop J.L., Lloyd G.K. Pharmacological characterization of neuronal acetylcholine gated ion channel receptor-mediated hippocampal norepinephrine and striatal dopamine release from rat brain slices. J. Pharmacol. Exp. Ther. 274:1995;224-230.
14. Sershen H., Balla A., Lajtha A., Vizi E.S. Characterization of nicotinic receptors involved in the release of noradrenaline from hippocampus. Neuroscience. 77:1997;121-130.
15. Vaughan P.F., Kaye D.F., Reeve H.L., Ball S.G., Peers C. Nicotinic receptor-mediated release of noradrenaline in the human neuroblastoma SH-SY5Y. J. Neurochem. 60:1993;2159-2166.
16. Vizi E.S., Harsing L.G. Jr., Zimanyi I., Gaal G. Release and turnover of noradrenaline in isolated median eminence: lack of negative feedback modulation. Neuroscience. 16:1985;907-916.
17. Vizi E.S., Sershen H., Balla A., Mike A., Windisch K., Juranyi Z., Lajtha A. Neurochemical evidence of heterogeneity of presynaptic and somatodendritic nicotinic acetylcholine receptors. Ann. NY Acad. Sci. 757:1995;84-99.